Investor Sigma-Tau Takes Another Slice of RegeneRx Pie
This article was originally published in The Pink Sheet Daily
Executive Summary
Cosmeceuticals could bring revenue in 2010, but safer beauty space is no “free lunch,” says troubled biotech’s CEO.
You may also be interested in...
Phase III Data With Scar Therapy Still Distant, Renovo Draws A Suitor
Pivotal results not due until 2011 – and skin peel drug needs a makeover.
Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences
With disappointing data from its lead program, the UK’s InterCytex is considering all options, including merger. In the U.S., Vanda is facing shareholder activism while Advanced Life Sciences is in the odd position of not being able to afford good news from FDA.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.